BioCryst Pharma (BCRX) Reports Q4 Loss of $0.40/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
February 23, 2022 7:00 AM ESTQ4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021
ORLADEYO net revenue in 2022 expected to be no less than $250 million
Pivotal trials in PNH and proof-of-concept trial in three renal indications currently enrolling patients
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... More
